scanance.
Sign inGet Premium
NU

Nu Skin Enterprises, Inc.

NUSConsumer DefensiveNASDAQ

Household & Personal Products · Last scanned May 30, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$1.49B
-14.3% YoY
Net Income
$160.2M
+209.3% YoY
EBITDA
$262.4M
+432.9% YoY
Free Cash Flow
$61.6M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. The $281.1M market capitalization puts NUS squarely in micro-cap range for its industry. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands.

Key stats
Market Cap$281.1M
P/E (TTM)5.36
Fwd P/E4.39
EPS$1.08
Beta1.02
52W Change-30.5%
Dividend Yield4.15%
ROE7.0%
Analysis

On the balance sheet, NUS has $200.4M in cash with $303.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $61.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 7.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.7% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $2.23B (2022) to $1.49B (2025), a 33% decline worth watching.

As with any equity investment, NUS carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NUS.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms